Aim: The purpose of the study is to establish the non-inferiority of right-sided inhibitory 1 Hz stimulation compared to left-sided intermittent theta burst stimulation (iTBS) in unipolar and bipolar depression. Design: A national, non-inferiority, register-based, randomized trial, unmasked, with two treatment arms. Primary objective: The primary objective is to determine if right-sided inhibitory 1-Hz stimulation to dorsolateral prefrontal cortex (DLPFC) is non inferior to iTBS in treating unipolar and bipolar depression by measuring reduction in Montgomery-Åsberg Depression Rating Scale, self-assessed version (MADRS-S) from baseline to end of treatment. Secondary objectives: Include testing for differences in: * Observer rated response according to Clinical Global Impression Scale-Improvement (≥2 point reduction CGI). * Response to treatment (a decrease of 50% on MADRS-S) * Self-rated global health measured with the EuroQual-group 5 Dimensions Scale Visual Analogue Scale (EQ-5D-VAS). * Drop-out from treatment. * Stimulation site pain measured with the Numerical Rating Scales (NRS). * Adverse events. * Admission and suicides within 6 months. * New treatment course of rTMS or ECT within 6 months * Remission (score \< 11 on the MADRS-S) * Memory impairment measured with the Comprehensive Psychopathological Rating Scale (CPRS). Study population: Patients with unipolar or bipolar depression. Sample size: 350 patients. Inclusion criteria: * At least 18 years of age at the time of inclusion. * A clinical diagnosis of unipolar or bipolar depression according to ICD-10. * Acceptance of rTMS. * A Swedish personal identity number. * Capable of giving informed consent. Exclusion criteria: • If the investigator judges one of the two treatment protocols inappropriate for the patient. Inclusion time: 2025-07-01 to 2029-01-01
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
350
Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that uses pulsed magnetic fields to activate or suppress specific brain regions. It is used to treat various conditions, including major depressive disorder, by inducing small electrical currents that stimulate nerve cells.
Intermittent theta-burst stimulation (iTBS) is a form of transcranial magnetic stimulation (TMS) used to modulate brain activity. It involves delivering brief bursts of magnetic pulses to specific brain regions, typically the left dorsolateral prefrontal cortex (DLPFC)
Unit for Brainstimulation
Örebro, Sweden
RECRUITINGUnit for Brainstimulation
Uppsala, Sweden
RECRUITINGreduction in the MADRS-S score
reduction in the MADRS-S score from baseline to the end of treatment
Time frame: 6 weeks
Stimulation site pain
Stimulation site pain (self-rated by patients using Numerical Rating Scales (NRS)).
Time frame: 15 minutes
CGI-I
Professionally determined response according to Clinical Global Impression Scale-Improvement (CGI-I)
Time frame: 6 weeks
Patient rate remission
Remission (score \< 11 on the MADRS-S)
Time frame: 6 weeks
Patient rated response
Response to treatment (a decrease of 50% on MADRS-S)
Time frame: 6 weeks
Self-rated EQ-5D-VAS
Self-rated global health measured with the EuroQual-group 5 Dimensions Scale Visual Analogue Scale (EQ-5D-VAS)
Time frame: 6 weeks
Drop-out
Drop-out from treatment for any reason within 30 sessions
Time frame: 6 weeks
Adverse events
Adverse events including severe adverse events
Time frame: 6 weeks, follow-up at 6 months
Self-rated EQ-5D-VAS at 6-month follow-up
Self-rated global health measured with the EQ-5D-VAS at 6-month follow-up
Time frame: 6 months
Self rated remission at 6-month follow-up
Self rated remission (score \< 11 on MADRS-S) at 6-month follow-up
Time frame: 6 months
Hospital admission
Hospital admissions for depression, hypomanic/manic switch, suicide attempts, and deaths including completed suicides within 6 months after randomization
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.